Search Results
Your search for 3 matches 15183 pages
Showing 3601 - 3650TOPAZ-1: Overall Survival Prolonged With First-Line Immunotherapy Plus Chemotherapy in Biliary Tract Cancer
For the first time, a phase III study has shown an overall survival benefit for upfront treatment using immunotherapy plus chemotherapy in advanced biliary tract cancer. In the TOPAZ-1 trial, the addition of the anti–PD-L1 agent durvalumab to gemcitabine plus cisplatin significantly improved...
Healthy Lifestyle and Development of Cardiovascular Disease or Type 2 Diabetes in Patients With or Without Cancer
In a study reported in JACC: CardioOncology, Yaogang Wang, PhD, of the School of Public Health, Tianjin Medical University, China, and colleagues found that fulfillment of more components of a healthy lifestyle was associated with a reduced risk of developing cancer in a baseline cancer-free cohort ...
Pretreatment Cardiovascular Disease and Events in Patients Receiving Curative-Intent Chemoradiation for Esophageal Cancer
In a Danish single-institution study reported in JACC: CardioOncology, Mette Marie A. Søndergaard, MD, of the Department of Cardiology, Aarhus University Hospital, Denmark, and colleagues found a high rate of undetected or inadequately treated preexisting cardiovascular disease (CVD) prior to...
AMA: CDC Quarantine and Isolation Guidance Is Confusing, Counterproductive
“Nearly 2 years into this pandemic, with Omicron cases surging across the country, the American people should be able to count on the Centers for Disease Control and Prevention (CDC) for timely, accurate, clear guidance to protect themselves, their loved ones, and their communities. Instead, the...
PALLAS Trial in Hormone Receptor–Positive, HER2-Negative Breast Cancer: Defining the Role of Adjuvant CDK4/6 Inhibition
Over the past 7 years, the introduction of combined endocrine therapy with cyclin-dependent kinase (CDK) 4/6 inhibitors resulted in a dramatic improvement in outcomes for patients with metastatic, hormone receptor–positive, HER2-negative breast cancer. Early attempts to modulate the cell cycle with ...
PALLAS Trial: No Invasive Disease–Free Survival Benefit With Addition of Adjuvant Palbociclib to Endocrine Therapy in Early Breast Cancer
As reported in the Journal of Clinical Oncology by Michael Gnant, MD, of the Comprehensive Cancer Center, Medical University of Vienna, and colleagues, the final analysis of the phase III PALLAS trial has shown no invasive disease–free survival benefit with the addition of adjuvant palbociclib to...
In All Candor, What Does CANDOR Bring to the Table in Relapsed or Refractory Multiple Myeloma?
An updated analysis of the phase III CANDOR study—recently reported by Usmani et al and summarized in this issue of The ASCO Post—confirmed a significant progression-free survival benefit for the combination of daratumumab, carfilzomib, and dexamethasone (KdD) over carfilzomib and dexamethasone...
Continued Progression-Free Survival Benefit With Carfilzomib/Dexamethasone/Daratumumab vs Carfilzomib/Dexamethasone in Relapsed or Refractory Multiple Myeloma
In an updated analysis of the pivotal phase III CANDOR trial reported in The Lancet Oncology, Saad Z. Usmani, MD, of Levine Cancer Institute/Atrium Health, and colleagues found that the addition of daratumumab to carfilzomib and dexamethasone (KdD) continued to show a large progression-free...
Compression Sleeves to Reduce Risk of Arm Swelling in Women Undergoing Surgery for Breast Cancer
In an Indian single-center study reported in the Journal of Clinical Oncology, Paramanandam et al found that the prophylactic use of compression sleeves reduced the risk of arm swelling in women with breast cancer undergoing axillary lymph node dissection. Study Details In the study, 301 evaluable...
Adverse Event Rates After Two Doses of mRNA COVID-19 Vaccine in Patients With vs Without Cancer
New research published by Shulman et al in JNCCN—Journal of the National Comprehensive Cancer Network confirmed that mRNA vaccines for COVID-19 are just as safe for people with cancer as they are for cancer-free individuals. Researchers from a single institution tracked short-term side effects from ...
Can An Intelligent Vacuum-Assisted Biopsy Algorithm Reliably Identify Patients With Breast Cancer Who Have a Pathologic Complete Response to Neoadjuvant Therapy?
In a study reported in the Journal of Clinical Oncology, Pfob et al developed a machine learning algorithm–based (intelligent) vacuum-assisted biopsy model that could identify patients with pathologic complete response (ypT0 and ypN0) to neoadjuvant therapy for breast cancer who may be able to...
Neoadjuvant Chemoradiotherapy vs Upfront Surgery in Resectable and Borderline Resectable Pancreatic Cancer
As reported in the Journal of Clinical Oncology by Versteijne et al, long-term follow-up of the Dutch phase III PREOPANC trial has shown an overall survival benefit among patients receiving neoadjuvant chemoradiotherapy vs upfront surgery for resectable and borderline resectable pancreatic cancer;...
Sugemalimab After Concurrent or Sequential Chemoradiation for Unresectable Stage III NSCLC
In an interim analysis of the Chinese phase III GEMSTONE-301 study reported in The Lancet Oncology, Zhou et al found that the PD-L1 inhibitor sugemalimab prolonged progression-free survival vs placebo in patients with locally advanced unresectable stage III non–small cell lung cancer (NSCLC)...
Efficacy of Trametinib in Recurrent Low-Grade Serous Ovarian Carcinoma
A study published by David Gershenson, MD, and colleagues in The Lancet reported that the MEK inhibitor trametinib reduced the risk of disease progression or death by 52% compared to standard-of-care therapies in low-grade serous ovarian carcinoma. The international, multicenter phase II/III trial...
Expert Point of View: Rona Yaeger, MD
Rona Yaeger, MD, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, New York, offered her thoughts on the findings of Morris et al for the combination regimen of encorafenib, cetuximab, and nivolumab in patients with microsatellite-stable BRAF V600E–mutated metastatic...
High Response Rate Seen With Nivolumab Added to Encorafenib and Cetuximab in BRAF V600E–Mutated Metastatic Colorectal Cancer
The combination of the BRAF inhibitor encorafenib with cetuximab and nivolumab produced responses in 50% of patients and disease control in 96% of patients with microsatellite-stable BRAF V600E–mutated metastatic colorectal cancer in a phase I/II trial reported at the 2022 ASCO Gastrointestinal...
Expert Point of View: Demetris Papamichael, MB, BS
The invited discussant of the SOLSTICE trial1 was Demetris Papamichael, MB, BS, Consultant Medical Oncologist at the Bank of Cyprus Oncology Centre and Associate Professor at St. George’s Hospital and Medical School, University of London. He said that although the study concluded...
SOLSTICE Trial: Trifluridine/Tipiracil Plus Bevacizumab in Metastatic Colorectal Cancer
For the treatment of metastatic colorectal cancer in patients unfit for intensive chemotherapy, trifluridine/tipiracil plus bevacizumab as first-line therapy was no more effective than capecitabine plus bevacizumab, investigators from the phase III SOLSTICE trial reported in a European Society for...
Pyrotinib and Capecitabine in HER2-Positive Breast Cancer With Brain Metastases
In the Chinese phase II PERMEATE trial reported in The Lancet Oncology, Yan et al found that the combination of the pan-HER receptor tyrosine kinase inhibitor pyrotinib plus capecitabine produced high intracranial response rates in women with HER2-positive breast cancer and brain metastases,...
Reduced-Intensity Chemoradiotherapy in EBV DNA–Selected Locoregionally Advanced Nasopharyngeal Carcinoma
In a Chinese phase II trial reported in the Journal of Clinical Oncology, Li et al found that treatment with two cycles of concurrent cisplatin and intensity-modulated radiotherapy (IMRT) was noninferior to three cycles in progression-free survival and associated with reduced toxicity in patients...
CheckMate 648: Nivolumab Plus Chemotherapy or Ipilimumab vs Chemotherapy in Previously Untreated Advanced Esophageal Squamous Cell Carcinoma
As reported in The New England Journal of Medicine by Doki et al, the phase III CheckMate 648 trial has shown improved overall survival with nivolumab combined with chemotherapy or ipilimumab vs chemotherapy alone in patients with previously untreated advanced esophageal squamous cell carcinoma, in ...
Use of Autologous Metastasis Mutation–Reactive TILs in Metastatic Breast Cancer
In a National Institutes of Health study reported in the Journal of Clinical Oncology, Zacharakis et al found that treatment with autologous tumor-infiltrating lymphocytes (TILs) reactive to mutations in metastatic lesions produced responses in patients with metastatic breast cancer. Study Details...
KRYSTAL-1: Adagrasib Controls Disease in Gastrointestinal Malignancies Beyond Colorectal Cancer
A disease control rate of 100% was achieved in gastrointestinal cancers treated with the KRAS G12C inhibitor adagrasib in the phase II KRYSTAL-1 trial, presented at the 2022 ASCO Gastrointestinal Cancers Symposium.1 The population included primarily those with pancreatic cancer; other noncolorectal ...
Can Weight Loss in Adulthood Reduce the Risk of Developing Colorectal Adenomas?
Weight loss for adults, particularly those who are overweight or obese, may reduce their risk of developing a type of polyp that may lead to colorectal cancer, according to a new study published by He et al in JNCI Cancer Spectrum. Losing weight from early to late adulthood (up to the mid-70s)—at...
Ibrutinib/Rituximab for Indolent Clinical Types of Mantle Cell Lymphoma
In a Spanish phase II trial (IMLC-2015) reported in the Journal of Clinical Oncology, Giné et al found that the combination of ibrutinib and rituximab produced a high complete response rate in previously untreated patients with indolent clinical types of mantle cell lymphoma. Study Details In the...
Romain Cohen, MD, PhD, on Metastatic Colorectal Cancer: Long-Term Follow-up on Nivolumab Plus Ipilimumab
Romain Cohen, MD, PhD, of Sorbonne University and Saint-Antoine Hospital, discusses phase II results of the GERCOR NIPICOL study, which suggests nivolumab plus ipilimumab at a fixed duration of 1 year continued to show durable activity in patients with chemoresistant microsatellite...
Addition of Sugemalimab to Platinum-Based Chemotherapy for Metastatic Squamous or Nonsquamous NSCLC
In the Chinese phase III GEMSTONE-302 trial reported in The Lancet Oncology, Caicun Zhou, MD, and colleagues found that the addition of the PD-L1 inhibitor sugemalimab to platinum-based chemotherapy improved progression-free survival in the first-line treatment of metastatic squamous or nonsquamous ...
Challenges for Oncologists as They Reach Retirement Age
In 2014, The ASCO Post spoke with Mark J. Clemons, MB BS, BMedSci, MSc, MD, FRCP, FRCPC, of Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada, about the retirement challenges faced by many oncologists. With market demand expected to exceed supply of oncologists soon, it is clear retirement is...
FDA Approves New Label Update for CAR T-Cell Therapy Axicabtagene Ciloleucel
On January 31, the FDA approved an update to the prescribing information for axicabtagene ciloleucel (Yescarta) to include use of prophylactic corticosteroids across all approved indications. Axicabtagene ciloleucel is now the first and only chimeric antigen receptor (CAR) T-cell therapy with...
Trastuzumab, Pertuzumab, and Docetaxel for Advanced HER2-Mutant NSCLC
In a French phase II trial (IFCT-1703-R2D2) reported in the Journal of Clinical Oncology, Julien Mazieres, MD, PhD, and colleagues found that the combination of trastuzumab, pertuzumab, and docetaxel produced durable responses in previously treated patients with advanced HER2-mutant non–small cell...
Assessing Value in Gastrointestinal Cancer Treatments
The era of precision oncology, in which molecular biomarkers are used to help guide drug delivery, has dovetailed with the emerging issues of value-based care and cost containment. To shed light on these issues and more, The ASCO Post spoke with Hanna K. Sanoff, MD, MPH, Clinical Medical Director...
Addition of Radiotherapy to Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC Refractory to PD-1/PD-L1 Inhibitor Therapy
In a phase II trial reported in The Lancet Oncology, Jonathan Schoenfeld, MD, and colleagues found that the addition of low-dose or hypofractionated radiotherapy to durvalumab plus tremelimumab did not improve objective response rates in patients with metastatic non–small cell lung cancer (NSCLC)...
SIOG Annual Conference Explores the Past, Present, and Future of Geriatric Oncology
The 2021 Annual Conference of the International Society of Geriatric Oncology (SIOG) was held on November 4–5. Although participants could not join the conference in person, attendees could still stay informed about the latest developments in geriatric oncology through the virtual platform. The...
Palbociclib Exposure and Discontinuation and Potential Impact on Outcome in the PALLAS Trial
In an analysis reported in the Journal of Clinical Oncology, Erica L. Mayer, MD, MPH, and colleagues found that early discontinuation and lower exposure intensity of oral palbociclib did not appear to account for the lack of invasive disease–free survival benefit observed with the addition of...
Binimetinib Plus Imatinib in Previously Untreated Patients With Advanced Gastrointestinal Stromal Tumor
In a single-center phase II trial reported in the Journal of Clinical Oncology, Chi et al found that the combination of the MET inhibitor binimetinib and the KIT inhibitor imatinib produced a high response rate in patients with previously untreated advanced gastrointestinal stromal tumor. As stated ...
David Cescon, MD, PhD, Comments on the MONALEESA Analyses
David Cescon, MD, PhD, Clinician Scientist at the Princess Margaret Cancer Centre in Toronto, Canada, was the invited discussant of the two MONALEESA analyses.1,2 He noted that the most recent overall survival analysis, presented at the European Society for Medical Oncology (ESMO) Congress 2021,...
MONALEESA Analyses Show Widespread Benefit for Ribociclib in Hormone Receptor–Positive, HER2-Negative Breast Cancer
Further analyses of the MONALEESA metastatic breast cancer trials have shown that the benefit of ribociclib plus endocrine therapy in the first-line setting extends to most intrinsic molecular subtypes and is consistent across multiple subgroups. The studies were presented at the 2021 San Antonio...
Addition of Spartalizumab to Dabrafenib/Trametinib for BRAF V600–Mutant Advanced Melanoma
As reported in the Journal of Oncology by Reinhard Dummer, MD, and colleagues, the phase III COMBI-i trial has shown no significant progression-free survival benefit with the addition of the anti–PD-1 antibody spartalizumab to dabrafenib and trametinib in patients with no prior systemic treatment...
Effect of ADT Use and Duration in Combination With Definitive Radiotherapy for Localized Prostate Cancer
In an individual patient-level meta-analysis reported in The Lancet Oncology, Amar U. Kishan, MD, and colleagues found that the addition of androgen-deprivation therapy (ADT) to definitive radiotherapy prolonged metastasis-free and overall survival in patients with localized prostate cancer. Longer ...
Addition of Perioperative Trastuzumab to Neoadjuvant Chemoradiation for Patients With HER2-Overexpressing Esophageal Adenocarcinoma
As reported in The Lancet Oncology by Howard P. Safran, MD, and colleagues, the phase III NRG Oncology/RTOG-101 trial has shown no significant disease-free survival benefit with the addition of perioperative trastuzumab to neoadjuvant chemoradiation in previously untreated patients with...
FDA Approves Tebentafusp-tebn for the Treatment of Unresectable or Metastatic Uveal Melanoma
On January 26, the U.S. Food and Drug Administration (FDA) granted approval to tebentafusp-tebn (Kimmtrak) for the treatment of adult patients with HLA-A*02:01–positive, unresectable or metastatic uveal melanoma. Tebentafusp’s approval establishes several firsts: as the first T-cell receptor...
Similar Efficacy—but Better Tolerability—for Ripretinib vs Sunitinib in Previously Treated Patients With Advanced GIST
In the INTRIGUE trial, the tyrosine kinase inhibitor ripretinib was not superior to sunitinib in the second-line treatment of patients with advanced gastrointestinal stromal tumors (GIST); however, the agent was better tolerated. These findings were presented by Michael C. Heinrich, MD, FACP, and...
Study Identifies Black Race as Risk Factor for Lymphedema After Axillary Dissection in Women With Breast Cancer
Black women with breast cancer had significantly higher rates of lymphedema after axillary lymph node dissection compared with Hispanic, White, and Asian women in a prospective study of breast cancer–related lymphedema presented at the 2021 San Antonio Breast Cancer Symposium (SABCS). In fact,...
Lenvatinib/Pembrolizumab vs Chemotherapy in Previously Treated Patients With Advanced Endometrial Cancer
As reported in The New England Journal of Medicine by Vicky Makker, MD, and colleagues, the phase III Study 309-KEYNOTE-775 trial has shown prolonged progression-free and overall survival with lenvatinib plus pembrolizumab vs physician’s choice of chemotherapy among previously treated patients with ...
Cancer Biologist Beatrice Mintz, PhD, FAACR, Dies at 100
The American Association for Cancer Research (AACR) issued the following statement regarding the passing of Beatrice Mintz, PhD, FAACR, a trailblazing pioneer in multiple fields of cancer biology, who died January 3, 2022, at the age of 100. Born on January 24, 1921, in New York, New York, Dr....
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Burundi
The ASCO Post is pleased to continue this occasional special focus on the worldwide cancer burden. In this issue, we feature a close look at the cancer incidence and mortality rates in Burundi. The aim of this special feature is to highlight the global cancer burden for various countries of the...
Pembrolizumab for Adjuvant Treatment of Stage IIB or IIC Melanoma
On December 3, 2021, pembrolizumab was approved for adjuvant treatment of adult and pediatric (≥ 12 years of age) patients with stage IIB or IIC melanoma following complete resection.1 Supporting Efficacy Data Approval was based on findings in the phase III, double-blind KEYNOTE-716 trial...
Daratumumab/Hyaluronidase-fihj and Carfilzomib in Multiple Myeloma
On November 30, 2021, daratumumab/hyaluronidase-fihj and carfilzomib were approved for use in combination with dexamethasone for adults with relapsed or refractory multiple myeloma who had one to three prior lines of therapy.1,2 Supporting Efficacy Data Approval was based on findings in a cohort...
Rituximab Plus Chemotherapy for Pediatric Mature B-Cell Non-Hodgkin Lymphoma and Mature B-Cell Acute Leukemia
On December 2, 2021, rituximab was approved for use in combination with chemotherapy for pediatric patients (≥ 6 months to 18 years) with previously untreated, advanced-stage, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia.1...
Tennessee Oncology Appoints Stephen Schleicher, MD, MBA, as Chief Medical Officer and Natalie Dickson, MD, as Chief Strategy Officer
Tennessee Oncology, one of the largest providers of oncology care in the country, announced that Stephen Schleicher, MD, MBA, has been appointed Chief Medical Officer (CMO) effective January 1, 2022. Natalie Dickson, MD, President and CMO, will remain in her role as President of the company while...
